Did Danaher Corporation Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

PRNewsWire • Mar 12, 2026

Danaher Corporation (DHR) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Danaher Corporation (DHR) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Seeking Alpha • Mar 3, 2026

Baron Durable Advantage Fund Q4 2025 Performance Review

During the fourth quarter, we initiated a new position in the leading energy-focused specialty contracting company, Quanta Services. Within the existing portfolio, our biggest addition during the quarter was to MSCI, a leading provider of indexes and investment decision support tools. We also added to our position in Danaher Corporation.

Seeking Alpha • Feb 26, 2026

Danaher Announces Quarterly Dividend

WASHINGTON, Feb. 24, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on April 24, 2026 to holders of record on March 27, 2026. ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health.

PRNewsWire • Feb 24, 2026

Danaher to Present at TD Cowen Health Care Conference

WASHINGTON, Feb. 24, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the TD Cowen Healthcare Conference in Boston, Massachusetts on Tuesday, March 3, 2025 at 1:50 p.m.

PRNewsWire • Feb 24, 2026

Harbor Large Cap Value Fund Q4 2025 Portfolio Review

During the fourth quarter, the Harbor Large Cap Value Fund returned 1.26%, underperforming its benchmark, the Russell 1000® Value Index, which returned 3.81%, and underperforming the 2.66% return of the S&P 500 Index. The top five contributors to relative performance during the fourth quarter were: Parker Hannifin, Capital One Financial, Amgen, Merck, and Danaher. The bottom five detractors from relative performance were: Lennar, Uber, Sony, Microsoft, and Teledyne Technologies.

Seeking Alpha • Feb 23, 2026

Danaher's $9.9B Masimo Deal Marks One of 2026's Largest Medtech Buyouts

Danaher (NYSE: DHR) is acquiring Masimo (NASDAQ: MASI) for $9.9 billion in an all-cash deal that values the medical technology company at $180 per share.

24/7 Wall Street • Feb 18, 2026

Masimo Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Masimo Corporation - MASI

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Masimo Corporation (NasdaqGS: MASI) to Danaher Corporation (NYSE: DHR). Under the terms of the proposed transaction, shareholders of Masimo will receive $180.00 in cash for each share of Masimo that they own. KSF is seeking to determine whether this consideration and the process that led to it are a.

Business Wire • Feb 19, 2026

Danaher to buy Masimo for $9.9 billion

Danaher will acquire pulse oximeter maker Masimo for $9.9 billion, the company said on Tuesday, as the contract research firm looks to bulk up its diagnostics portfolio.

Reuters • Feb 17, 2026

Danaher to acquire Masimo in $9.9B all-cash deal

Danaher Corporation (NYSE:DHR) announced it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ: MASI) in an all-cash transaction valued at approximately $9.9 billion, as the life sciences and diagnostics company looks to expand its patient monitoring capabilities. Under the terms of the agreement, Danaher will acquire all outstanding Masimo common shares for $180 per share in cash.

Proactive Investors • Feb 17, 2026